that's interesting! A commissioned short report. Lots of company analysis reports are paid-for commissioned reports, so why not commission a negative company report?
Except the Culper report attacked Acadia, and if Baker Bros wanted a scrip merger of Acadia and Neuren, then they would want Acadia's share price to be high….wouldn’t they?
so what are UBS's motives, if they commissioned the culper report and why are they still driving down the NEU price?
maybe UBS is working for a bigger pharma who wants to buy both companies super-cheap? Baker Bros may still benefit from that deal, as it allows them to exit Acadia…
who knows?
…
I wonder if a forced margin call is also at work here…perhaps UBS knows this too…a big holder who didn’t buy all his stash outright but as a margin loan purchase?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)